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AttOaSA rejection is a complex process, which requires
interactions between different cell types and a variety of
soluble factors, such as cytokines. In this review we
discuss the role ofcytokines in the induction and effector
phases of the rejection process and in the induction and
maintenance of allospecific graft tolerance. Furthermore,
we discuss the feasibility of clinical graft function moni-
toring by measuring cytokines and the possibilities for
intervention in the cytokine network in order to inhibit
graft rejection and eventually obtain graft acceptance.
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Introduction
Cytokines are proteins, which act as soluble me-
diators and regulators of immune responses. They
perform their actions by binding to specific mem-
brane-bound receptors and act in a paracrine or
autocrine fashion. Different cell types, not only
leukocytes, can produce the same cytokine or react
to the same cytokine. So, one cytokine can have a
range of differential effects on various different target
cells (pleiotropy). Furthermore, two different
cytokines can have the same effect (redundancy).
Cytokines are able to positively or negatively influ-
ence the production and function of one another.
The complexity of the cytokine network should be
kept in mind, while interpreting experimental or
clinical findings as discussed in this review.
One of the immune responses in which cytokines
are considered to play an important role is allograft
rejection. The process of rejection has been studied
carefully and starts to become more clear. 1-3 During
the induction phase of rejection, T-cell receptor (TcR)
recognition of the foreign MHC molecule results in T-
cell activation, expression of the interleukin (IL)-2
receptor (R) and production IL-2, which in an
autocrine fashion induces clonal expansion of the
activated T cells. During T cell activation, soluble
(s)IL-2R are released. It is thought that CD4 T
lymphocytes are essential for initiation of graft rejec-
tion and CD8/T cells are more important in the
effector phase of rejection. In this phase, production
of IL-2 and other cytokines induces influx and pro-
liferation of CD8 cytotoxic T cells, natural killer (NK)
cells and macrophages. This inflammatory process
will lead to tissue destruction and dysfunction of the
graft. Cytokines can influence this process at several
levels (Table 1). IL-1, produced by macrophages, acts
as an accessory signal from the antigen presenting
cell (APC) for T cell proliferation.6,7 IL-2 is a growth
factor for T lymphocytes, induces T lymphocyte
cytotoxicity and stimulates NK cell activity. Inter-
feron (IFN)-7 activates macrophages, cytotoxic T cells
and NK cells and induces increased expression of
MHC class and II molecules in this way increasing
the allogenicity of the graft. Tumour necrosis factor
(TNF)-{x increases the MHC class expression and
activates neutrophils.1-12 Apart from these activities,
cytokines may have direct cytotoxic effects on the
grafted tissue. 13
Since CD4 T cells are of such importance for graft
rejection, T-helper (Th)l-Th2 subsets have been
studied for their potential role in regulating the
rejection process. Both in mice and in human, differ-
ent Th cell clones have been described, which can be
distinguished by the different sets of cytokines they
produce. 14,15 Thl cells produce IL-2, IFN-, and
Table 1. Cell sources of cytokines relevant in transplantation
CTL Thl Th2 NK Bcell Monocytes/ Other
macrophages
IL-1
IL-2 + +
IL-4
IL-5
IL-6
IL-10
IFN-7 + +
TNF-(x + +
TNF-I + +
+ + +
+ +
+
+
+ + +
+ +
aCTL, cytotoxic T lymphocytes.
bOther cells producing these cytokines are fibroblasts, epithelial
cells etc.
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lymphotoxin (LT, also known as TNF-I), while Th2
cells produce IL-4, IL-5, IL-6 and IL-10. Other
cytokines, such as IL-3 and TNF-, are produced by
both Th subsets.
Different functions have been assigned to the
different Th subsets. Thl cells mediate delayed-type
hypersensitivity (DTH), anti-viral and anti-tumoral
cytotoxic effects, while Th2 cells provide help for B
cell differentiation and antibody formation. These
two Th subsets are able to influence each others
cytokine production and proliferation. IFN-,, pro-
duced by Thl cells, inhibits Th2 cell proliferation and
cytokine production. 16 IFN7 also antagonizes the
activity of IL-4 in B cell activation and isotype pro-
duction. 14 The Th2 cytokine IL-10, inhibits the pro-
duction of Thl cytokines while IL-4 inhibits Thl cell
proliferation. 17,8 Since cellular cytotoxicity plays an
important role in allograft rejection, Thl cells are
thought to dominate in this process. On the other
hand, the suppression of these allospecific Thl cells
by Th2 cells could be a mechanism of graft accept-
ance. Altered cytokine gene expression and produc-
tion during graft rejection provides a logical target to
redirect the observed shifts in the Thl-Th2 balance
interfering with the cytokine network.
To further elucidate the role of cytokines in clinical
and experimental allograft rejection and survival, we
first focus on the detection of cytokines during the
rejection process and during graft acceptance. Then
we describe the approaches that have been used to
interfere in the cytokine network and future pros-
pects for therapeutic intervention.
Detection of cytokines during graft
rejection
There are two reasons for detecting cytokines
during allograft rejection. The first is to find a reliable
and preferably non-invasive method to monitor graft
function. If certain cytokines are found to be early
predictors of acute rejection this enables us to start
rejection therapy as soon as possible and to monitor
the success of this therapy. The second reason is to
learn more about which cytokines play a role in the
rejection process and therefore might be good targets
for immunomodulation. We think that therapeutic
intervention in the earliest (induction) phase of rejec-
tion is preferable to intervention in the effector phase
in order to redirect the immune response and achieve
long-term allograft survival. Therefore, we consider
cytokines appearing in the induction phase of
more importance to serve as targets for
immunomodulation than cytokines appearing late in
rejection.
The advantage of animal models for graft rejection
is that proper controls, including syngeneic grafts
and non-grafted tissue can be examined for cyto-
kine expression. Furthermore, in general, no
immunosuppressive drugs are being used in these
models.
In the clinical setting, immunosuppressive drugs
are routinely used for the prevention of organ trans-
plant rejection. Immunosuppressive drugs like
cyclosporin A (CsA) and glucocorticoids can inhibit
TNF and IL-6 production,19-2 while the anti-CD3 mAb
OKT3 and anti-thymocyte globulin (ATG) can in-
crease serum IL-6 and TNF-0t leve|s.22-24
Table 2 summarizes the cytokines described to be
involved in allograft rejection.
Detection ofsystemic cytokines: In the clinical setting
a lot of effort has been made to find a single or few
cytokines in the serum, urine or bile, that permit
monitoring graft rejection. In kidney, liver or lung
transplantation, serum levels of It-6,23’25’26 TNF-,27-29
IL-2, and sIL-2R3-4 have been shown to increase in
relation to graft rejection. Serial monitoring was nec-
essary, since not the absolute levels of IL-6 or slL-2R,
but rather a rise of these levels indicated the devel-
opment of rejection.25,26,1,5 However, the measured
cytokine levels have low sensitivity and specificity
regarding rejection diagnosis. TNF-, IL-2 and sIL-2R
levels were found to be elevated in some cases of
stable graft function.29-1,3 IL-6, TNF-0t and slL-2R lev-
els were increased in the early postoperative period
and elevations of IL-6, TNF-0t or sIL-2R levels were
found during episodes of infection.2’2’27’-4
Yoshimura et al. suggested that serum IL-6 levels or
even better the ratio of IL-6 to CsA trough value may
discriminate rejection from CsA nephrotoxicity. Pos-
sibly, measurements of TNF-29 or IL-23 in the urine
of renal allograft recipients or IL-63 in the bile, as
shown in a rat hepatic allograft model, will have
more value in discriminating allograft rejection from
infection or non-immunological graft dysfunction.
These studies demonstrate that systemic cytokine
measurements are not reliable enough to differenti-
ate rejection from infection. Therefore, they cannot
be used for monitoring and histological tissue analy-
sis remains the standard for diagnosis of rejection.
Whether these cytokines are involved in the mecha-
nism of allograft rejection, as has been suggested in
a few of the above-mentioned studies, is in our
opinion doubtful. Based on their paracrine and
autocrine activity, the detection of cytokines in the
periphery is not likely to reflect the local activities
within the graft. It is much more likely that cytokines
Table 2. Detection of cytokines implicated in allograft rejection
Cytokines References
Systemic
In situ animal
models
In situ clinical
transplantation
IL-2, slL-2R, IL-6, TNF-o
IL-2, IL-4, (IFN-7), (TNF-I)
IL-2, IL-5, IL-6, IFN-7, TNF-(x
23, 25-35
44, 45
46-50
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that are systemically present, such as TNF- and IL-6
are involved in the inflammatory process of an ongo-
ing rejection process and are rather nonspecific
markers in the serum. Interference with these
cytokines could diminish the development of in-
flammation, but a more preferable target for
immunomodulation would be those particular
cytokines, that are involved in the induction phase of
the local rejection process in order to create a new
immunological balance and graft acceptance.
In situ detection ofcytokines duringgraft rejection: In
order to get more insight into which cytokines are
involved in the rejection process, cytokines have
been detected in the graft in experimental and clini-
cal settings. For in situ detection of cytokines several
techniques have been used. Northern blot analysis,
reverse transcription (RT)-PCR and in situ hybridiza-
tion were used to detect cytokine mRNA within the
graft. In sponge matrix allografts, i.e. sponges con-
taining allogeneic cells, the exudate was tested
for cytokine proteins. Furthermore, the local pro-
duction of cytokines was investigated using
immunohistochemistry or cultures of graft-infiltrating
cells (GIC). All of these techniques have their own
advantages and disadvantages. For example, if
cytokine mRNA is to be detected, one cannot con-
clude that the protein is also present, since the
production of cytokines can be regulated at post-
transcriptional level. In situ hybridization indicates
the localization of cytokine production and is also
rather sensitive, but is a difficult and time-consnming
technique. RT-PCR is an extremely sensitive method,
but this method gives no information about the cell-
type that produces the detected cytokines.
Immunohistochemistry is able to demonstrate the
cytokine-producing cells. However, most cytokines
are not retained in the cytosol, but are directly
secreted after translation. This may cause false nega-
tive results. On the other hand, it is difficult to
discriminate between the cytokine producing cells
and the target cells for these cytokines. Especially
interpretations concerning Thl-Th2 imbalances
should be made very carefully. This also counts if
cytokines are detected in supernatants of cultured
graft infiltrating cells. It has been shown that culture
conditions, such as added cytokines, can dictate the
outcome of the cytokine pattern produced.32 The
analysis of mRNA of cultured cells is also unreliable,
since manipulating the cells can cause not only
induction of a particular cytokine mRNA, but also the
level of instable cytokine mRNA to decline.43
Two studies in a murine cardiac allograft model44,45
used the extremely sensitive reverse transcription
PCR method to detect cytokine mRNA in normal
tissue, isografts and allografts at several days after
grafting. Their results were quite similar. The
cytokines that were detectable could be divided into
three groups. The first group of cytokines .can be
detected in normal tissue, isografts and allografts and
consists of IL-I[, IL-5, IL-6, TNF-0t and TGF-. The
second group, including IL-I{x and IL-3, is expressed
in both isografts and allografts. These two groups
seem to represent cytokines which are induced in
response to the grafting procedure and are not cor-
related with the rejection process itself. The last and
probably the most important group consists of IL-2
and IL-4. These cytokines are only present in
allografts, which suggests they play a role in allograft
rejection. However, the two studies show inconsist-
ent data on two cytokines, TNF-[. and IFN-,. Dallman
et al.44 showed that TNF-I can only be detected in
allografts, while Morgan et al.45 also detected this
cytokine in isografts. IFN-,, however, was only found
in allografts by Morgan et al., while Dallman et al.
detected IFN-, mRNA in normal tissue and in
isografts as well, though the levels were lower than
in the allografts. This difference in cytokine pattern
remains unexplained. Interestingly, Dallman et al.
found that IL-2, IL-4 and TNF-, the cytokines that are
expressed only in the allografts, were all transcribed
transiently, their expression being maximal at 4-5
days after transplantation. Thereafter the expression
declined before clinical signs of rejection appeared,
suggesting these cytokines play a role in the initia-
tion of rejection.
In the clinical setting in situ detection of cytokines
in rejecting allografts has been compared with grafts
without signs of rejection. In situ hybridization of
human renal biopsies showed that normal kidney
tissue or biopsies from patients with stable graft
function do not significantly express IL-6, TNF-0t or
IFN-, transcripts.46 During acute rejection, however,
the grafts showed significant levels of IL-6 mRNA, but
not TNF-0 or IFN-, mRNA. The IL-6 mRNA was
expressed in many different cell types, such as
glomerular cells, tubular epithelium and vascular
endothelium. The significance of the IL-6 production
by these nonimmune cells remains unclear. Using the
same technique on irreversibly rejected kidney grafts,
TNF-0t mRNA could be detected in macrophage-like
infiltrating cells.47 Immunohistochemistry showed
that these cells actually produced TNF- protein.
Glomerular cells and tubular epithelium cells prob-
ably were target cells for TNF-0t, since TNF- protein
could be detected, but no TNF-0t mRNA was found
in these cells. The results of mRNA detection during
allograft rejection may be influenced by the organ
investigated. In human liver allografts IL-I, IL-4,
IL-6 and TNF-0t mRNA was expressed in rejecting
allografts and in grafts without signs of rejection.48
Only IL-5 mRNA was associated with liver graft rejec-
tion.. All the above-mentioned data are derived from
grafts, in which the rejection process had developed
quite far, as graft dysfunction was .already apparent,
and the rejection sometimes even irreversible. So, the
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cytokines detected may play a role in the graft rejec-
tion, but may also be rather nonspecific mediators of
tissue inflammation and destruction. Two studies,
using RT-PCR on fine-needle aspirates, were able to
detect IL-2 mRNA49 and IFN-y mRNA5 in samples,
taken before clinical rejection. Since the expression
was transient, sequential analysis is required to use
this method to predict graft rejection.
Detection ofcytokines during allografi acceptance: In
animal models, the induction of allograft tolerance
has succeeded by using several different protocols,
such as a preoperative donor-specific transfusion
(DST) or anti-CD4 monoclonal antibody (mAb) treat-
ment.51-53 Determination of the changes in the
cytokine profile in these accepted grafts compared
with rejecting allografts, may clarify the mechanism
by which this state of tolerance is maintained and
may indicate ways to manipulate the immune system
in order to obtain tolerance. Strangely, intragraft
events, which have been ascribed to cytokines, such
as mononuclear cell infiltration, allospecific cytotoxic
T cells and elevated expression of MHC class and
II antigens, arestill apparent in tolerized grafts54 and
renal allografts with stable graft function.55
In a rat kidney allograft model, in which tolerance
was induced by DST, graft infiltrating cells from
tolerant rats were unable to produce IL-2 in vitro,
expressed lower levels of the IL-2R and showed
lower proliferation in response to IL-2 than cells from
untreated rats. 56 In a comparable model, tolerized rat
heart allografts showed a lower expression of IL-2
and IFN-7 mRNA and a different kinetics of these
messages than rejecting allografts.57 Strong evidence
that the downregulation of IL-2 or IFN-7 mRNA plays
a role in the development of graft tolerance is pro-
vided by the fact that simultaneous administration of
IL-2 or IFN-y and the DST abrogates the tolerizing
effect. It is still unclear whether this downregulation
of Thl cytokines is the mechanism of tolerance
induction or whether Th2 cells play a role in sup-
pressing these Thl cytokines.
After induction of tolerance, using several different
strategies, it has been shown that IL-2 and IFN-y
mRNA were downregulated, whereas IL-4 and IL-10
(Th2 cytokines) mRNA expression remained at the
same level or even increased.58 However, there is no
proof that the source of these cytokines is indeed T
lymphocytes. Recently, it has been shown, that IL-10
mRNA is detectable in many organs of a normal
mouse and is expressed at the same level in nude
mice or SCID mice, suggesting independence of T
and B cells. 59
Anti-CD4 mAb treatment has resulted in graft ac-
ceptance in several animal models. Partial depletion
of CD4* T cells in mice resulted in a higher expres-
sion of IL-4 mRNA and a lower expression of IFN-7
mRNA, as detected by in situ hybridization in puri-
fled CD4 T cells.6 In other studies, using anti-CD4
mAb, long term renal allograft survival and abroga-
tion of accelerated cardiac rejection were accompa-
nied by diminished IL-2 expression and preserved IL-
4 expression, suggesting that the Thl-Th2 dichotomy
does play a role in immunosuppression.61,2 Addi-
tional evidence is provided by the finding that adop-
tive transfer of a bm12-specific Th2 cell line to B6
mice resulted in prolongation of bm12 skin grafts,
whereas BALB/c third party grafts were rejected.63 It
is interesting to note that IL-4 can be detected both
early in the rejection process44 and during graft ac-
ceptance. This finding awaits further clarification.
Strategies interfering with cytokine effects
CsA and FK506 are important immunosuppressive
drugs, that are widely used for preventing organ
allograft rejection. It is known for several years now
that their immunosuppressive mechanism is based
on inhibition of T cell signal transduction pathways
leading to activation of cytokine gene expression.4
Besides these established regimens, alternative ways
to interfere with cytokine effects have been studied
(Table 3).
Monoclonal orpolyclonal antibodies: Since cytokines
have been shown to be associated with allograft
rejection, several strategies have been studied to
interfere with cytokine function in order to prolong
graft survival.
Monoclonal and polyclonal antibodies against
cytokines have been shown to prolong allograft
survival in several animal models. Anti-IFN-7 mAb
blocked MHC class II disparate skin graft rejection in
mice, but had no effect on MHC class disparate skin
graft rejection.5 Anti-IL-2, anti-TNF-ot and anti-LT
antibodies79 were able to prolong rat cardiac
allograft survival, when given as the only therapy. In
the same model, anti-IFN-7 antibodies alone failed to
prolong graft survival compared with untreated con-
trols.,1 However, in combination with CsA, anti-
IFN-y antibodies prolonged allograft survival in a
synergistic way.,2 This synergistic action with CsA,
that permits lowering of the CsA dose, thereby de-
creasing its potential nephrotoxicity, is also seen
using anti-TNFmt antibodies.8,69 Furthermore, it has
been shown that combining anti-LT with anti-TNF-{x
Table 3. Strategies interfering with cytokine effects
Modulator Targets References
CsA, FK506 IL-2
Antibodies IL-2, IFN-7,
TNF-(z, TNF-,
IL-2R cells
Cytokine conjugated toxins IL-2R* cells
Soluble receptors IL-1, IL-4
Cytokines (IL-4, IL-10) Th2 subset
64
65-69, 76-85
86, 87
88, 89
98, Dallman et aL
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mAb ameliorates graft survival, compared with anti-
TNF-0t mAb treatment alone.68
Although these antibody treatments directed against
single cytokines have some effect, graft survival times
are not impressive. One of the reasons for this
finding could be the property of cytokines to mediate
local, i.e. in the graft, short-distance effects. There-
fore the local antibody concentration might not be
sufficient to neutralize its target cytokine. However,
there is evidence that the neutralizing antibodies
indeed reach the graft, since 125I-labelled anti-IL-2
mAb was detectable in the graft.6 Furthermore, local
effects of the mAb, such as diminished mononuclear
cell infiltration, no expression of MHC class anti-
gens and modification of immunohistologic staining
pattern of TNF-0t, were readily visible.7,9,72 Another
explanation for the disappointing results with
cytokine-directed antibodies is the redundancy of
the cytokine system. Neutralizing the activity of one
cytokine probably makes another take over. The
striking redundancy of the cytokine system was
again demonstrated by the finding, that IL-2 and IL-
4 knock-out mice were less affected in the develop-
ment and function of their T cell system than ex-
pected.73.4
Another approach to interfere in the cytokine net-
work, by using mAb directed against the IL-2R
(CD25), has been shown to be more successful. Not
only the number of publications on the use of this
mAb, but also the fact that this treatment is already
used in clinical trials, are indicative for its success.
Anti-IL-2R mAb therapy differs from anti-cytokine
mAb therapy in that it acts on IL-2R bearing cells and
not just on soluble proteins. Since high-affinity IL-2R
is only expressed on activated T cells and not on
resting T cells, this approach seems more specific
than other established immunosuppressive therapies
using ATG, OKT3 or CsA75 The mechanism of the
anti-IL-2R induced immunosuppression is still not
clear. Depletion of IL-2R cells, modulation of the
IL-2R or blocking of the IL-2-IL-2R interaction have
been proposed to play a role.:-9 In animal models
anti-IL-2R mAb have been used to inhibit GVHD and
organ allograft rejection.7<1 Prospective clinical
trials have shown that anti-IL-2R treatment is equally
effective as ATG for the prevention of renal allograft
rejection.82-4
The use of mouse or rat mAb in clinical transplan-
tation is hampered by the development of human
anti-antibodies, that subsequently lead to high clear-
ance rate of the mAb and abrogation of their effect.
Therefore, ’humanized’ mAb have been produced,
combining the rodent complementarity-determining
regions with constant regions and framework of
human antibodies. A ’humanized’ anti-IL-2R mAb,
that was less immunogenic and had a longer half-life
than its murine form, significantly prolonged cardiac
allograft survival in cynomolgus monkeys.5 As ’hu-
manized’ mAb were being developed, molecular
engineering offered an alternative approach for se-
lectively attacking IL-2R cells. Cytotoxic substances,
such as Pseudomonas exotoxin (PE) or Diphtheria
toxin were coupled to IL-2, thereby targeting and
killing IL-2R cells. IL-2-PE40 and DAB486-IL-2 were
able to inhibit allograft survival in animal models.<
Soluble cytokine receptors: In biological fluids of both
animals and humans, cytokine binding proteins have
been found, that later appeared to be soluble forms
of cytokine receptors, like sIL-2R, slL-4R and sTNFR.
They generally have the same binding affinity for
their ligand as the membrane receptors and therefore
are able to competitively inhibit cytokine binding to
membrane receptors and subsequently their effects
on target cells. Soluble cytokine receptors are consid-
ered to be naturally occurring cytokine inhibitors and
have the advantage of higher affinity and being non-
immunogenic over neutralizing mAb. Their potential
as therapeutic agents in inflammatory disease and
sepsis has been shown. In a cardiac allograft model
in mice, sIL-1R and slL-4R have been shown to
somewhat prolong the allograft survival.,9
The efficacy of treatment with soluble cytokine
receptors is based on scavenging the relevant
cytokine. Therefore, it is crucial to have the soluble
cytokine receptor present in the serum with a long
half-life. The linking of two sTNFR molecules to the
Fc portion of a single human IgG1 molecule resulted
in a dimeric form of sTNFR with significantly higher
affinity for TNF than the monomeric sTNFR. More-
over, this complex is detectable in serum during 4-
5 days, being significantly increased over unbound
sTNFR. This dimeric sTNFR was very effective in in
vivo neutralizing endogenous TNF and protecting
mice from lethal endotoxaemia.9,91 Since anti-TNF
mAb have been shown to be effective in prolonging
allograft survival,,9 this agent might have a similar
or even more potent effect on allograft rejection.
Using soluble cytokine receptors, one should keep in
mind that they are also capable of acting as cytokine
carriers, protecting them from proteolytic cleavage,
prolonging their half-live in the circulation and there-
fore having an agonistic instead of an antagonistic
effect.92 The ratio in the presence of the cytokine and
its soluble receptor probably determines the biologi-
cal outcome.
Strategies for Thl-Th2 ’skewing’: The assumption
that Thl cells are responsible for rejection, whereas
Th2 cells may act as suppressor cells and induce graft
acceptance has led to the idea that ’skewing’ of the
Thl-Th2 ratio towards Th2 dominance might inhibit
graft rejection. In vitro studies have shown that
cytokines can direct the differentiation of Th cells to
one of the subsets. In the presence of IFN-, Thl cell
development is enhanced,38 whereas IL-4 enhances
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the development of Th2 cells. 39,4,93 IL-10 does not
seem to direct bulk cultures towards Th2 cytokine
producing cells, though anti-IL-10 mAb did induce
Thl-like cells.93 Treatment of allograft recipients with
IL-4 or IL-10 could have the same ’skewing’ effect.
Furthermore, IL-10 not only inhibits the production
of Thl cytokines, but also has anti-inflammatory
properties by inhibiting IL-1, IL-6 and TNF-o synthe-
sis by macrophages.94 In vivo interference in the
dominance of one of the Th subsets has already
succeeded in a number of inflammatory models.
Giving anti-IL-4 mAb before or within the first week
of Leishmania major infection rendered a suscepti-
ble mouse strain resistant to the parasite,95 but anti-
IL-10 mAb had no effect. The other way around, IL-
4 promoted the Th2 response to the parasite, but did
not render the infected recipient susceptible.96 Anti-
IFN-T mAb did render Tranosoma cruzi resistant
mice susceptible to the infection.97 In an allogeneic
graft model, the use of anti-IFN-7 or anti-IL-2 mAb has
not been very effective in prolonging allograft sur-
vival, as we described earlier. There have been two
groups reporting on the effect of administration of
Th2 cytokines, IL-4 and IL-10, on allogeneic re-
sponses. Though cardiac allograft rejection (M.
Dallman, personal communication) and enlargement
of the draining lymphnode98 were inhibited, no tol-
erance was induced. Furthermore, systemic adminis-
tration of these cytokines could have some draw-
backs, such as stimulation of B lymphocytes, anti-
body-production and increased incidence of infec-
tions. Also, there is evidence that systemic adminis-
tration of cytokines, in this case IFN-y, may lead to
a downregulation of endogenously produced
cytokine.99
Prospects for therapeutic strategies: Strategies direc-.
ted against a single cytokine in the form of mAb,
soluble cytokine receptors or other agents are not
likely to be successful in inhibiting graft rejection.
Molecular engineered proteins, on the other hand,
such as the dimeric form of sTNFR, may be useful to
inhibit the intragraft inflammation and systemic ef-
fects of graft rejection. Other than in parasitic models,
systemic administration of cytokines will probably
not be able to interfere with the local processes
leading to graft rejection. The increasing knowledge
on requirements for T cell activation and the different
signalling pathways leading to cytokine production
and T cell subset activation, should enable us to
interfere with this process in order to establish
allospecific tolerance. T cdl activation requires be-
sides TcR-MHC interaction costimulatory signals
coming from interaction of cell surface molecules on
the APC and the T cells. 1,11 Indeed, in vitro studies
have shown that TcR signalling in the absence of
costimulatory signals results in T cell anergy.12,13
Furthermore, this anergy can be induced in Thl
clones but not in Th2 clones.14-m6 The CD28-B7
interaction seems to play a critical role in the
costimulation of T cells. 11’17 In vivo blocking of this
interaction inhibits cardiac allograft rejection18 and
induces long term survival of pancreatic
xenografts,m9 Further studies in in vitro and animal
models for tolerance should lead to strategies result-
ing in anergy of allospecific Thl cells and induction
of allospecific ’suppressor’ Th2 cells and thereby to
allospecific tolerance.
Concluding remarks
Cytokines are involved in the allograft rejection
process. However, the relevance of systemic
cytokine measurements in order to predict graft rejec-
tion is limited, since elevated cytokine levels are
found both during rejection and infection. In the
induction phase of rejection, a major role is probably
played by IL-2 and IFN-y together with or in balance
with IL-4. During the effector phase, many different
cytokines may mediate the inflammation. The local
rejection process is not easily inhibited by systemic
administration of anti-cytokines or cytokines. Inter-
vention in intercellular signalling may lead to a new
immunological balance and a state of graft tolerance,
based on Thl anergy and/or Th2 suppression.
References
1. Hayry P. Mechanisms of rejection. Curt Opin Immunol 1989; 1: 1230-1235.
2. Colvin RB. Cellular and molecular mechanisms of allograft rejection. Annu Rev
Med 1990; 41: 361-375.
3. Wecker H, Auchincloss HJ. Cellular mechanisms of rejection. Curr Opin Immunol
1992; 4: 561-566.
4. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and
clinical application. Ann Intern Med 1990; 113: 619-627.
5. Strom TB. The cellular and molecular basis of allograft rejection: what do
know? Transplant Proc 1988; 20: 143-146.
6. Kaye J, Gillis S, Mizel SB, et al. Growth of cloned helper T cell line induced by
monoclonal antibody specific for the antigen receptor: interleukin is required
for the expression of receptors for interleukin 2.Jlmmunol 1984; 133:1339-1345.
7. Durum SK, Schmidt JA, Oppenheim JJ. Interleukin 1: immunological perspec-
tive. Annu Rev Immunol 1985; 3: 263-287.
8. O’Garra A. Interleukins and the immune system 1. Lancet 1989; i: 943-947.
9. O’Garra A. Interleukins and the immune system 2. Lancet 1989; |: 1003-1005.
10. Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino
MAJ. Activation of human polymorphonuclear neutrophil functions by interferon-
gamma and tumor necrosis factor. J lmmunol 1985; 135: 2069-2073.
11. Collins T, Lapierre LA, Fiers W, Strominger JL, Pober JS. Recombinant human
tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B
antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl
Acad Sci USA 1986; 83: 446-450.
12. Tracey KJ, Vlassara H, Cerami A. Cachectin/tumour necrosis factor. Lancet 1989;
i: 1122-1126.
13. Maessen JG, Buurman WA, Kootstra G. Direct cytotoxic effect of cytokines in
kidney parenchyma: possible mechanism of allograft destruction. Transplant
Proc 1989; 21: 309-310.
14. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine
secretion lead to different functional properties. Annu Rev Immunol 1989; 7:
145-173.
15. Romagnani S. Human TH1 and TH2 subsets: doubt Immunol Today
1991; 12: 256-257.
16. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regu-
lation. I. IFN-gamma inhibits the proliferation of Th2 but not Thl murine helper
T lymphocyte clones. JImmunol 1988; 140: 4245-4252.
17. Fiorentino DF, Bond MW, Mosmann TR. Two types of T helper cell. IV.
Th2 clones secrete factor that inhibits cytokine production by Thl clones. JExp
Med 1989; 170: 2081-2095.
18. Mosmann TR, Moore KW. The role of IL-10 in crosssregulation of TH1 and TH2
responses. Immunol Today 1991; 12: 49-53.
408 Mediators of Inflammation Vol 3. 1994
Cytokines in transplantation
19. Nguyen DT, Eskandai MK, DeForge LE, et al. Cyclosporin A modulation of tumor
necrosis factor gene expression and effects in vitro and in vivo. JImmunol 1990;
144: 3822-3828.
20. Beutler B, ,Cerami A. Cachectin: than tumor necrosis factor. NEnglJMed
1987; 316: 379-385.
21. Yoshimura N, Kahan BD, Oka T. The in vivo effect of cyclosporine interleukin-
gene expression in renal transplant recipients. Transplant Proc 1991; 23:
958-96O.
22. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor,
interleukin-2, and gamma-interferon in after injection of OKT3 monoclonal
antibody in kidney transplant recipients. Transplantation 1989; 4"7: 606-608.
23. Yoshimura N, Oka T, Kahan BD. Sequential determinations of interleukin
levels immunodiagnostic tool to differentiate rejection from nephrotoxicity
in renal allograft recipients. Transplantation 1991; 51: 172-176.
24. Debets JM, Leunissen KM, Hooff HJ, der Linden CJ, Buurman WA.
Evidence of involvement of tumor necrosis factor in adverse reactions during
treatment of kidney allograft rejection with antithymocyte globulin. Transplanta-
tion 1989; 4"7: 487-492.
25. Van Oers MH, Van der Heyden AA, Aarden LA. Interleukin (IL-6) in and
urine of renal transplant recipients. Clin Exp Immunol 1988; "71: 314-319.
26. Kita Y, Iwaki Y, Demetris AJ, Starzl TE. Evaluation of sequential
interleukin-6 levels in liver allograft recipients. Transplantation 1994; 5"7:
1037-1041.
27. Maury CP, Teppo AM. Raised levels of cachectin/tumor necrosis factor
alpha in renal allograft rejection. JExpMed 1987; 166: 1132-1137.
28. Imagawa DK, Millis JM, Olthoff KM, et al. The role of tumor necrosis factor in
allograft rejection. I. Evidence that elevated levels of tumor necrosis factor-alpha
predict rejection following orthotopic liver transplantation. Transplantation 1990;
5t3: 219-225.
29. McLaughlin PJ, Aikawa A, Davies HM, et al. Evaluation of sequential plasma and
urinary tumor necrosis factor alpha levels in renal allograft recipients. Transplan-
tation 1991; 51: 1225-1229.
30. Simpson MA, Madras PN, Cornaby AJ, et al. Sequential determinations of urinary
cytology and plasma and urinary lymphokines in the management of renal
allograft recipients. Transplantation 1989; 4"7: 218-223.
31. Colvin RB, Preffer FI, Fuller TC, et al. A critical analysis of and urine
interleukin-2 receptor assays in renal allograft recipients. Transplantation 1989;
48: 800-805.
32. Perkins JD, Nelson DE, Rakela J, Grambsch PM, Krom RA. Soluble interleukin-2
receptor level indicator of liver allograft rejection. Transplantation 1989; 4"7:
77-81.
33. Humbert M, Emilie D, Cerrina J, et al. Soluble interleukin receptor and neopterin
levels after lung/heart-lung transplantations absence of predictive value
for late allograft rejection. Transplantation 1991; 52: 1092-1094.
34. Gascoigne AD, Shenton BK, White MD, Colquhoun IW, Dark JH, Corris PA. The
value of plasma-soluble interleukin receptor monitoring in lung transplantation.
Transplantation 1993; 56: 1029-1031.
35. Young Fadok TM, Simpson MA, Madras PN, Dempsey RA, O’Connor K, Monaco
AP. Predictive value of pretransplant IL-2 levels in kidney transplantation. Trans-
plant Proc 1991; 23: 1295-1296.
36. Cohen N, Gumbert M, Birnbaum J, et al. An improved method for the detection
of soluble interleukin receptors in liver transplant recipients by flow cytometry.
Transplantation 1991; 51: 417-421.
37. Tono T, Monden M, Yoshizaki K, et al. Biliary interleukin 6 levels indicators
of hepatic allograft rejection in rats. Transplantation 1992; 53: 1195-1201.
38. Gajewski TF, Joyce J, Fitch FW. Antiproliferative effect of IFN-gamma in immune
regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte
clones using recombinant IL-2 and recombinant IFN-gamma.Jlramuno11989; 143:
15-22.
39. Le Gros G, Ben Sasgon SZ, Seder R, Finkelman FD, Paul WE. Generation of
interleukin (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 required
for in vitro generation of IL-4-producing cells. J Exp Med 1990; 1"72: 921-929.
40. Swain SL, Weinberg AD, Englilsh M, Huston G. IL-4 directs the development of
Th2-1ike helper effectors. JImmunol 1990; 145: 3796-3806.
41. Betz M, Fox BS. Regulation and development of cytochrome c-specific IL-4-
producing T cells. Jlmmunol 1990; 145: 1046-1052.
42. Swain SL, Huston G, Tonkonogy S, Weinberg A. Transforming growth factor-beta
and IL-4 helper T cell precursors to develop into distinct effector helper
cells that differ in lymphokine secretion pattern and cell surface phenotype. J
Immunol 1991; 14"7: 2991-3000.
43. Dallman MJ, Montgomery RA, Larsen CP, Wanders A, Wells AF. Cytokine gene
expression: analysis using Northern blotting, polymerase chain reaction and in situ
hybridization. Immunol Rev 1991; 9: 163-179.
44. Dallman MJ, Larsen CP, Morris PJ. Cytokine gene transcription in vascularised
organ grafts: analysis using semiquantitative polymerase chain reaction. JExpMed
1991; 174: 493-496.
45. Morgan C, Pelletier R, Hernandez C, et al. Cytokine mRNA expression during
development of acute rejection in murine cardiac allografts. TransplantProc 1993;
25: 114-116.
46. Vandenbroecke C, Caillat Zucman S, Legendre C, et al. Differential in situ
expression of cytokines in renal allograft rejection. Transplantation 1991; 51:
602-609.
47. Morel D, Normand E, Lemoine C, et al. Tumor necrosis factor alpha in human
kidney transplant rejection analysis by in situ hybridization. Transplantation
1993; 55: 773-777.
48. Martinez OM, Krams SM, Sterneck M, et al. Intragraft cytokine profile during
human liver allograft rejection. Transplantation 1992; 53: 449-456.
49. Dallman MJ, Roake J, Hughes D, Toogood G, Morris PJ. Sequential analysis of IL-
gene transcription in renal transplants. Transplantation 1992; 53: .683-685.
50. Nast CC, Zuo XJ, Prehn J, Danovitch GM, Wilkinson A, Jordan SC. Gamma-
interferon gene expression in human renal allograft fine-needle aspirates. Trans-
plantation 1994; 5"7: 498-502.
51. Wood KJ, Evins J, Morris PJ. Suppression of renal allograft rejection in the rat by
class antigens purified erythrocytes. Transplantation 1985; 39: 56-62.
52. Cobbold SP, Martin G, Waldmann H. The induction of skin graft tolerance in major
histocompatibility complex-mismatched primed recipients: primed T cells
be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur J
Immunol 1990; 20: 2747-2755.
53. Pearson TC, Darby CR, Bushell AR, West LJ, Morris PJ, Wood KJ. The assessment
of transplantation tolerance induced by anti-CD4 monoclonal antibody in the
murine model. Transplantation 1993;" 55: 361-367.
54. Wood KJ, Hopley A, Dallman MJ, Morris PJ. Lack of correlation between the
induction of donor class and class II major histocompatibility complex antigens
and graft rejection. Transplantation 1988; 45: 759-767.
55. Rush DN, Henry SF, Jeffery JR, Schroeder TJ, Gough J. Histological findings in
early routine biopsies of stable renal allograft recipients. Transplantation 1994;
5"7: 208-211.
56. Dallman MJ, Shiho O, Page TH, Wood KJ, Morris PJ. Peripheral tolerance to
alloantigen results from altered regulation of the interleukin pathway. JExpMed
1991; 173: 79-87.
57. Bugeon L, Cuturi MC, Hallet MM, Paineau J, Chabannes D, Soulillou JP. Peripheral
tolerance of allograft in adult rats characterization by low interleukin22
and interferon-gamma mRNA levels and by strong accumulation of major
histocompatibility complex transcripts in the graft. Transplantation 1992; 54:
219-225.
58. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems. The
differential activation of Th2-1ike effector cells in peripheral tolerance. Transplan-
tation 1992; 53: 1281-1294.
59. Broski AP, Halloran PF. Tissue distribution of IL-10 mRNA in normal mice.
Evidence that component of IL-10 expression is T and lcelMndependent and
increased by irradiation. Transplantation 1994; 5"7: 582-592.
60. Field EH, Rouse TM, Fleming AL, Jamali I, Cowdery JS. Altered IFN-gamma and
IL-4 pattern lymphokine secretion in mice partially depleted of CD4 T cells by
anti-CD4 monoclonal antibody. J Immunol 1992; 149: 1131-1137.
61. Papp I, Wieder KJ, Sablinski T, et al. Evidence for functional heterogeneity of rat
CD4+ T cells in vivo. Differential expression of IL-2 and IL-4 mRNA in recipients
of cardiac allografts. JImmunol 1992; 148: 1308-1314.
62. Siegling A, Lehmann M, Riedel H, et al. A nondepleting anti-rat CD4 monoclonal
antibody that suppresses T helper l-like but not T helper 2-like intragraft
lymphokine secretion induces long-term survival of renal allografts. Transplanta-
tion 1994; 57: 464-467.
63. Maeda H, Takata M, Takahashi S, Ogoshi S, Fujimoto S. Adoptive transfer of
t(h)2-1ike cell line prolongs MHC class-II antigen disparate skin allograft survival
in the Int Immunology 1994; 6: 855-862.
64. Bierer BE, Hollander G, Fruman D, Burakoff SJ. Cyclosporin A and FK506:
molecular mechanisms of immunosuppression and probes for transplantation
biology. Curr Opin Immunol 1993; 5: 763-773.
65. Rosenberg AS, Finbloom DS, Maniero TG, Van der Meide PH, Singer A. Specific
prolongation of MHC class II disparate skin allografts by in vivo administration of
anti-IFN-gamma monoclonal antibody. Jlmmunol 1990; 144: 4648-4650.
66. Sakagami K, Ohsaki T, Ohnishi T, Saito S, Matsuoka J, Orita K. The effect of anti-
interleukin monoclonal antibody treatment the survival of rat cardiac
allograft. J Surg Res 1989; 46: 262-266.
67. Imagawa DK, Millis JM, Olthoff KM, et al. The role of tumor necrosis factor in
allograft rejection. II. Evidence that antibody therapy against tumor necrosis
factor-alphfi and lymphotoxin enhances cardiac allograft survival in rats. Trans-
plantation 1990; 50: 189-193.
68. Imagawa DK, Millis JM, Seu P, et al. The role of tumor necrosis factor in allograft
rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival
in rats with acute rejection. Transplantation 1991; 51: 57-62.
69. Boiling SF, Kunkel SL, Lin H. Prolongation of cardiac allograft survival in rats by
anti-TNF and cyclosporine combination therapy. Transplantation 1992; 53:
283-286.
70. Didlake RH, Kim EK, Sheehan K, Schreiber RD, Kahan BD. Effect of combined
anti-gamma interferon antibody and cyclosporine therapy cardiac allograft
survival in the rat. Transplantation 1988; 45: 222-223.
71. Paineau J, Priestley c, Fabre J, et al. Effects of gamma interferon and interleukin-
2, and of gamma-interferon antibodies, the rat immune response against
allografts. Transplant Proc 1989; 21: 999-1001.
72. Gugenheim J, Tovey M, Gigou M, et al. Prolongation of heart allograft survival in
rats by interferon-specific antibodies and low dose cyclosporin A. Transplant Int
1992; (Suppl 1): $460-$461.
73. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I. Development and function
of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991;
352: 621-624.
74. Kuhn R, Rajewsky K, Muller W. Generation and analysis of interleukin-4 deficient
mice. Science 1991; 254: 707-710.
75. Waldmann TA. The structure, function, and expression of interleukin-2 receptors
normal and malignant lymphocytes. Science 1986; 232: 727-732.
76. Kupiec Weglinski JW, .Tilney NL, Stunkel KG, et al. Agonistic and antagonistic
interactions of anti-interleukin receptor monoclonal antibodies in rat recipients
of cardiac allografts. Transplantation 1989; 47: 11-16.
77. Stunkel KG, Grutzmann R, Diamantstein T, Kupiec. Weglinski JW, Schlumberger
HD. Anti-interleukin-2 receptor monoclonal antibody therapy in rats: comparison
Mediators of Inflammation. Vol 3. 1994 409
A. C. T. M. Vossen and H. F.J. Savelkoul
of the effector mechanisms mediated by variant murine isotypes. Transplant Proc
1989; 21: 1003-1005.
78. Tellides G, Dallman MJ, Morris PJ. Mechanism of action of interleukin-2 receptor
(IL-2R) monoclonal antibody (MAb) therapy: target cell depletion inhibition Of
function? Transplant Proc 1989; 21: 997-998.
79. Kirkman RL, Barrett LV, Gaulton GN, et al. The effect of anti-interleukin-2 receptor
monoclonal antibody allograft rejection. Transplantation 1985; 40: 719-722.
80. Ferrara JL, Marion A, Mclntyre JF, Murphy GF, Burakoff SJ. Amelioration of acute
graft host disease due to minor histocompatibility antigens by in vivo admin-
istration of anti-interleukin receptor antibody. Jlmmuno11986; 137: 1874-1877.
81. Diamantstein T, Mouzaki A, Osawa H, et al. Inhibition of allograft rejection and
organ-specific autoimmune disease by anti-interleukin-2 receptor (IL-2R)-targeted
immunotherapy. The action of anti-IL-2R monoclonal antibodies and synergistic
effect of cyclosporin A. Dev Biol Stand 1988; 69: 177-184.
82. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of
anti-Tac monoclonal antibody in human renal transplantation. Transplantation
1991; 51: 107-113.
83. Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of
monoclonal antibody against the interleukin-2 receptor (33B3.1) compared
with rabbit antithymocyte globulin for prophylaxis against rejection of renal
allografts [see comments]. NEnglJMed 1990; 322: 1175-1182.
84. Hiesse C, Kriaa F, Alard P. et al. Prophylactic of the IL-2 receptor-specific
monoclonal antibody LO-Tact-1 with cyclosporin A and steroids in renal transplan-
tation. Tramplant Int 1992; 5 (Suppl 1): S444-S447.
85. Brown PSJ, Parenteau GL, Dirbas FM, et al. Anti-Tac-H, humanized antibody to
the interleukin receptor, prolongs primate cardiac allograft survival. Proc Natl
Acad Sci USA 1991; 88: 2663-2667.
86. Kirkman RL, Bacha P, Barrett LV, Forte S, Murphy JR, Strom TB. Prolongation of
cardiac allograft survival in murine recipients treated with diphtheria toxin-
related interleukin-2 fusion protein. Transplantation 1989; 47: 327-330.
87. Lorberboum Galski H, Barrett LV, Kirkman RL, et al. Cardiac allograft survival in
mice treated with IL-2-PE40. Proc Natl Acad Sci USA 1989; 86: 1008-1012.
88. Fanslow WC, Sims JE, Sassenfeld H, et al. Regulation of alloreactivity in vivo by
soluble form of the interleukin-1 receptor. Science 1990; 248: 739-742.
89. Fanslow WC, Clifford KN, Park LS, et al. Regulation of alloreactivity in vivo by IL-
and the soluble IL-4 receptor. Jlmmunol 1991; 147: 535-540.
90. Haak Frendscho M, Marsters SA, Mordenti J, et al. Inhibition of TNF by TNF
receptor immunoadhesion. Comparison to anti-TNF monoclonal antibody.
JImmunol 1994; 152: 1347-1353.
91. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF)
receptors effective therapeutic agents in lethal endotoxemia and function
simultaneously both TNF carriers and TNF antagonists. JImmunol 1993; 151:
1548-1561.
92. Fernandez Botran R. Soluble cytokine receptors: their role in immunoregulation.
FASEBJ 1991; 5: 2567-2574.
93. Hsieh CS, Heimberger AB, GoldJS, O’Garra A, Murphy KM. Differential regulation
of T helper phenotype development by interleukins and 10 in alpha beta T-
cell-receptor transgenic system. Proc Natl Acad Sci USA 1992; 89: 6065-6069.
94. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A. IL-10 inhibits
cytokine production by activated macrophages. Jlmmuno11991; 147: 3815-3822.
95. Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM. Cure of
murine leishmaniasis with anti-interleukin monoclonal antibody. Evidence for
T cell-dependent, interferon gamma-independent mechanism. J Exp Med 1990;
171: 115-127.
96. Chatelain R, Varkila K, Coffman RL. IL-4 induces Th2 response in Leishmania
major-infected mice. JImmunol 1992; 142: 1182-1187.
97. Silva JS, Morrissey PJ, Grabstein KH, Mohler KM, Anderson D, Reed SG.
Interleukin 10 and interferon gamma regulation of experimental Trypanosoma
cruze infection. J Exp Med 1992; 175: 169-174.
98. Goldman M, Velu T. Interleukin-10 antiinflammatory and
immunosuppressive cytokine. Abstract presented at the International conference
trends in clinical and experimental immunosuppression, Geneva, 1994.
99. Brok HP, Heidt PJ, der Meide PH, Zurcher C, Vossen JM. Interferon-gamma
prevents graft-versus-host disease after allogeneic bone transplantation in
mice. Jlmmunol 1993; 151: 6451-6459.
100. Liu Y, Linsley PS. Costimulation of T-cell growth. Curr Opin Immunol 1992; 4:
265-270.
101. Jenkins MK, Johnson JG. Molecules involved in T-cell costimulation. Curr Opin
Immunol 1993; 5: 361-367.
102. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990;
24: 1349-1356.
103. Jenkins MK, Mueller D, Schwartz RH, et al. Induction and maintenance of anergy
in mature T cells. Adv Exp Med Biol 1991; 292: 167-176.
104. Jenkins MK, Pardoll DM, Mizuguchi J, Chused TM, Schwartz RH. Molecular events
in the induction of nonresponsive state in interleukin 2-producing helper T-
lymphocyte clones. Proc Natl Acad Sci USA 1987; 84: 5409-5413.
105. Williams ME, Shea CM, Lichtman AH, Abbas AK. Antigen receptor-mediated
anergy in resting T lymphocytes and T cell clones. Correlation with lymphokine
secretion patterns. JImmunol 1992; 149: 1921-1926.
106. Gilbert KM, Weigle WO. B cell presentation of tolerogenic signal to Th clones.
Cell lmmunol 1992; 139: 58-71.
107. Lenschow DJ, Bluestrone JA. T cell co-stimulation and in vivo tolerance. Curr Opin
Immunol 1993; 5: 747-752.
108. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is
required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89:
11102-11105.
109. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic
pancreatic islet grafts induced by CTLA41g [see comments]. Science 1992; 257:
789-792.
ACKNOWLEDGEMENTS. We thank Professor Dr R. Benner and G. J. M. Tibbe for
critical review of the manuscript. A.V. is supported by the Dutch Kidney Foundation.
Received 22 August 1994;
accepted 5 September 1994
410 Mediators of Inflammation Vol 3. 1994
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
